Susquehanna International Group
INZY

Susquehanna International Group’s Inozyme Pharma INZY Stock Holding History

Susquehanna International Group’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33,000
Closed -$132K – 13125
2025
Q2 		$132K Buy
+33,000
New +$81.7K ﹤0.01% 11601
2024
Q3 		– Sell
-16,100
Closed -$71.8K – 12476
2024
Q2 		$71.8K Buy
+16,100
New +$78.1K ﹤0.01% 11231
2024
Q1 		– Sell
-19,200
Closed -$81.8K – 12715
2023
Q4 		$81.8K Sell
19,200
-153,400
-89% -$545K ﹤0.01% 11461
2023
Q3 		$725K Buy
172,600
+158,000
+1,082% +$804K ﹤0.01% 7368
2023
Q2 		$81.3K Sell
14,600
-4,900
-25% -$29K ﹤0.01% 11095
2023
Q1 		$112K Buy
+19,500
New +$51.5K ﹤0.01% 11198

Susquehanna International Group's INZY Position: Q3 2025 in Review

Susquehanna International Group sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 224,981 shares — an estimated $900K sold.

Susquehanna International Group first reported a position in INZY in Q3 2020 and held it in 9 quarters. The position peaked at $900K in Q2 2025. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

  • Susquehanna International Group reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 224,981 Inozyme Pharma shares in Q3 2025, an estimated $900K.
  • Susquehanna International Group first reported a position in Inozyme Pharma in Q3 2020 and held it in 9 quarters.
  • Susquehanna International Group's Inozyme Pharma position peaked at $900K in Q2 2025.
  • 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.